entertainment -WSS

entertainment

author：Wikipedia 2025-08-12 06:45:25 - browse：2673

This image provided by Eisai in January 2023 shows vials and packaging for their medication, Leqembi. — Illustration: Alex Hogan/STAT; Photo: Eisai via AP

Seven months after US drug regulators fully approved Biogen’s treatment for Alzheimer’s disease, only about 2,000 patients are taking the medicine nationwide, the company said Tuesday.

Biogen’s chief executive, Christopher A. Viehbacher, said as the firm released fourth-quarter earnings that he had expected the slow uptake and sees considerable demand for the medication. He told reporters that 3,800 patients with early-stage Alzheimer’s have signed up on multiple registries to receive the drug, called Leqembi, as of last month.

Before patients can get the drug, which costs $26,500-a-year, they must undergo a brain scan or a spinal tap to confirm that they have build-up of deposits of a sticky toxic protein called beta-amyloid that is a hallmark of the disease.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： Medical mystery: When an infection after surgery isn’t what it seems

WSS

FDA cancer chief on how to get things done: ‘Don’t tell anybody'

What is STAT's opinion section for?

Pediatricians' group reaffirms support for gender

Pope greeted like rockstar, appears revitalized at 'Catholic Woodstock' in Portugal

Jesse Tyler Ferguson makes friendship bracelets for Taylor Swift's Eras Tour

Publishing genetic code of viruses could cause disaster

hotspot

entertainment

knowledge

Duchenne breakthrough therapy leaves behind pioneering families

Does Medicare's free annual wellness visit do any good?

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Pediatricians' group reaffirms support for gender

Medicare proposal to cover medical devices draws a mixed reaction

Rivals hope for voter 'fatigue' as Trump's woes mount but base stays loyal: ANALYSIS

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Russian court extends detention of American musician

Drug repurposing or repositioning? The language matters

Eat, drink, but be wary — 4 foods that interact with medications

focus

Medical school prerequisites are outdated

Rock icon Freddie Mercury pre

Readout LOUD Podcast: Lilly's obesity drug, the power of radiation

Readout Newsletter: Ozempic panic wanes, Legend x Novartis, etc.

Readout Newsletter: Ozempic panic wanes, Legend x Novartis, etc.

Parkland mass shooting to be reenacted for lawsuit

hotspot

hotspot

hotspot

focus